Semagacestat

Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC50s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC50 of 14.1 nM. Semagacestat can be used for the research of alzheimer's disease[1].

Product Specifications

CAS Number

[425386-60-3]

Product Name Alternative

LY450139

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Amyloid-β; Notch; γ-secretase

Type

Reference compound

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Semagacestat.html

Purity

99.56

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C([C@H]1NC([C@@H](NC([C@H](C(C)C)O)=O)C)=O)N(CCC2=C1C=CC=C2)C

Molecular Formula

C19H27N3O4

Molecular Weight

361.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Mitani Y, et al. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci. 2012 Feb 8;32 (6) :2037-50.|[2]Elvang AB, et al. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem. 2009 Sep;110 (5) :1377-87.|[3]Justice NJ, et al. Posttraumatic stress disorder-like induction elevates β-amyloid levels, which directly activates corticotropin-releasing factor neurons to exacerbate stress responses. J Neurosci. 2015 Feb 11;35 (6) :2612-23.|[4]Portelius E, et al. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis. 2010;21 (3) :1005-12.|[5]Junki Hirano, et al. Characterization of SPP inhibitors suppressing propagation of HCV and protozoa. Proc Natl Acad Sci U S A. 2017 Dec12;114 (50) :E10782-E10791.